Stock Events

Stock Events

Sareum

0

30

+€0.00+0% 00:00 Today

Statistics

Day High

-

Day Low

-

52W High

-

52W Low

-

Volume

-

Avg. Volume

-

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

Nov 2Expected

Q4 2025

Next

-0.01

0.32

0.65

0.99

Expected EPS

N/A

Actual EPS

N/A

Financials

-Profit Margin

Unprofitable

2019

2020

2021

2022

2023

2024

0Revenue

-5.22MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RYH.STU. It's not an investment recommendation.

Lloyds Banking Group

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Bristol-Myers Squibb

Bristol Myers Squibb, with a strong portfolio in oncology, cardiovascular, and immunoscience, competes in the development of novel therapies, similar to Sareum's research focus.

Merck & Co., known for its innovative cancer treatments and vaccines, competes with Sareum in the oncology and immunotherapy sectors.

Pfizer, with a broad range of therapeutic areas including oncology, competes with Sareum in the development and commercialization of cancer treatments.

Roche Holding AG, specializing in biotechnology products for oncology, immunology, and infectious diseases, competes with Sareum in the cancer research and development space.

Novartis AG, focusing on innovative medicines in areas like oncology and immunology, competes with Sareum in the development of new treatments for cancer and autoimmune diseases.

Amgen, with a focus on human therapeutics in areas including oncology/hematology, competes with Sareum in the development of cancer and autoimmune disease treatments.

Eli Lilly and Company, focusing on cancer, endocrinology, and immunology, competes with Sareum in the development of therapies for various diseases, including cancer.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, known for its innovative biotechnology products in oncology and immunology, competes with Sareum in the research and development of treatments for cancer and autoimmune diseases.

About

Sareum Holdings plc operates as a specialized pharmaceutical company, primarily focused on discovering and advancing innovative therapeutic compounds for treating both cancer and autoimmune conditions. The firm develops small-molecule drugs, utilizing its proprietary Sareum Kinase Inhibitor Library as its core drug discovery platform. Its development portfolio currently features programs targeting Checkpoint Kinase 1, Aurora+FLT3 kinase, and TYK2/JAK1 kinase. Sareum has also forged strategic partnerships with the Hebei Medical University Biomedical Engineering Center and Sierra Oncology, Inc. Founded in 2003, the company is headquartered in Cambridge, United Kingdom.

Show More

CEO

Stephen Barry Parker DPhil

Employees

5

Country

United Kingdom

ISIN

GB00B02RFS12

WKN

000A3DWCH

Listings

0 Comments

Share your thoughts

FAQs

What is Sareum stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Sareum stocks are traded under the ticker RYH.STU.

When is the next Sareum earnings date?▼

Sareum is going to release the next earnings report on March 31, 2027.

What is Sareum revenue for the last year?▼

Sareum revenue for the last year amounts to 0 EUR.

What is Sareum net income for the last year?▼

RYH.STU net income for the last year is -5.22M EUR.

How many employees does Sareum have?▼

As of November 2, 2026, the company has 5 employees.

In which sector is Sareum located?▼

Sareum operates in the Health & Wellness sector.

When did Sareum complete a stock split?▼

The last stock split for Sareum was on March 1, 2022 with a ratio of 1:50.

Where is Sareum headquartered?▼

Sareum is headquartered in Cambridge, United Kingdom.